These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15832762)

  • 1. [Conclusions from CHARM interview with Prof. Veselin Mitrovich, Bad Nauheim. Strong evidence: more help for weak hearts].
    Mitrovic V
    MMW Fortschr Med; 2005 Mar; 147(13):48-9. PubMed ID: 15832762
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K
    Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract]   [Full Text] [Related]  

  • 4. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    McKelvie RS
    J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CHARM study--new strategy for the treatment of heart failure].
    Hasegawa H; Komuro I
    Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
    Pocock S; Wang D; Wilhelmsen L; Hennekens CH
    Am Heart J; 2005 May; 149(5):939-43. PubMed ID: 15894981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [AT1 blockers against heart failure. The charm of polypharmacy].
    MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
    [No Abstract]   [Full Text] [Related]  

  • 10. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
    Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
    [No Abstract]   [Full Text] [Related]  

  • 11. [CHARM].
    Momomura S
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():431-6. PubMed ID: 16981575
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
    Kudo Y; Komuro I; Akazawa H
    Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
    [No Abstract]   [Full Text] [Related]  

  • 13. Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
    Pitt B
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):70-1. PubMed ID: 16265371
    [No Abstract]   [Full Text] [Related]  

  • 14. The CHARM program: study design leads to findings of clinical and public health importance.
    Hennekens CH; Pfeffer MA; Swedberg K
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):124-6. PubMed ID: 17562782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving outcomes in chronic heart failure.
    Komajda M
    Drugs Today (Barc); 2006 Dec; 42 Suppl C():29-36. PubMed ID: 17245479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR
    Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
    [No Abstract]   [Full Text] [Related]  

  • 18. The CHARM programme raises the profile of candesartan cilexetil in the treatment of chronic health failure.
    Cardiovasc J S Afr; 2004; 15(1):42-3. PubMed ID: 15095753
    [No Abstract]   [Full Text] [Related]  

  • 19. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure.
    McKelvie RS
    Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):9-16. PubMed ID: 19105762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of candesartan, enalapril and their combination in congestive heart failure].
    Rapezzi C
    Ital Heart J Suppl; 2000 Mar; 1(3):429-30. PubMed ID: 10815278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.